From Raising $56M, Revolution Medicines Drops Old Work and Turns to Cancer:

Mark Goldsmith, Revolution Medicines
Mark Goldsmith, Revolution Medicines

Photo of Revolution Medicines CEO Mark Goldsmith by company.